Biological Treatment of Psoriasis A Different Life

Leyla Abed Rassul, Sabah Ramadan Hussein Ahmed

Abstract: Psoriasis has a significant detrimental effect on quality of life and is linked to both anxiety and depression. The introduction of biologics has improved treatment outcomes, but it is not well understood how patients feel about these gains. Aims of the current study was to address the advantages and disadvantages of biologics as a first - line treatment option and revise treatment guidelines in light of new research. The comorbid conditions are included in our discussion. Additionally; to discuss the effect of COVID - 19 on psoriasis patients. Furthermore; to investigate the daily activities of psoriasis patients getting biological therapy in order to better understand their requirements and the care they receive. Methodology The current study was searched using a variety of key words such as biologic therapy psoriasis, psoriatic arthritis, Type of psoriasis, psoriasis andor complications, psoriasis andor COVID, psoriasis andor interstitial pneumonia, inteleukin - 23 and interluekin - 17. Those articles were derived from the data related to Psoriasis and reported cases were conducted utilizing seven electronic databases (CINAHL, MEDLINE, ProQuest, PubMed, Scopus, Science Direct, and Cochrane) for studies published in various languages from January 2023 to September 2023. According to the findings, psoriasis is a prevalent inflammatory skin illness with major medical and psychosocial comorbidities that is primarily genetically determined. The number of therapy options available to people with psoriasis is growing as a result of improvements in our understanding of the diseases aetiology. biological treatments that reduce systemic inflammation may improve cardiovascular outcomes in psoriasis patients. Similar to how metabolic syndromecan be well controlled by medicine or lifestyle modifications, psoriasis signs and symptoms may improve as a result.

Keywords: biologic therapy, psoriasis, biologics, psoriasis, psoriatic arthritis, tumour necrosis factor, inteleukin-23, interluekin-17, Psoriasis, biologics, COVID-19, psoriasis